M. Weller, W. Wick, and K. Aldape, Nature Reviews Disease Primers, vol.1, p.15017, 2015.

Q. T. Ostrom, H. Gittleman, and P. Liao, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014, Neuro-Oncol, vol.19, pp.1-88, 2017.

M. Weller, M. Van-den-bent, and J. C. Tonn, European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, vol.18, pp.315-344, 2017.

B. M. Alexander, E. Galanis, and W. Yung, Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group, Neuro-Oncol, vol.17, pp.180-188, 2015.

M. D. Prados, S. A. Byron, and N. L. Tran, Toward precision medicine in glioblastoma: the promise and the challenges, Neuro-Oncol, vol.17, pp.1051-63, 2015.

Q. Liang, L. Li, and J. Zhang, CDK5 is essential for TGF-?1-induced epithelial-mesenchymal transition and breast cancer progression, Sci Rep, vol.3, p.2932, 2013.

R. D. Dorand, J. Nthale, and J. T. Myers, Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity, Science, vol.353, pp.399-403, 2016.

N. Kwiatkowski, T. Zhang, and P. B. Rahl, Targeting transcription regulation in cancer with a covalent CDK7 inhibitor, Nature, vol.511, pp.616-636, 2014.

E. Chipumuro, E. Marco, and C. L. Christensen, CDK7 inhibition suppresses super-enhancerlinked oncogenic transcription in MYCN-driven cancer, Cell, vol.159, pp.1126-1165, 2014.

C. Huang, A. Lujambio, and J. Zuber, CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma, Genes Dev, vol.28, pp.1800-1814, 2014.

K. C. Goh, V. Novotny-diermayr, and S. Hart, TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties, Leukemia, vol.26, pp.236-279, 2012.

S. Alvarez-fernández, M. J. Ortiz-ruiz, and T. Parrott, Potent antimyeloma activity of a novel ERK5/CDK inhibitor, Clin Cancer Res Off J Am Assoc Cancer Res, vol.19, pp.2677-87, 2013.

D. Annibali, J. R. Whitfield, and E. Favuzzi, Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis, Nat Commun, vol.5, p.4632, 2014.

L. Rieger, M. Weller, and A. Bornemann, BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study, J Neurol Sci, vol.155, pp.68-75, 1998.

H. Strik, M. Deininger, and J. Streffer, BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy, J Neurol Neurosurg Psychiatry, vol.67, pp.763-771, 1999.

A. C. Murphy, B. Weyhenmeyer, and J. Noonan, Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis, Apoptosis Int J Program Cell Death, vol.19, pp.629-671, 2014.

K. Seystahl, I. Tritschler, and E. Szabo, Differential regulation of TGF-?-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma, Neuro-Oncol, vol.17, pp.254-65, 2015.

K. Seystahl, A. Papachristodoulou, and I. Burghardt, Biological role and therapeutic targeting of TGF-?3in Glioblastoma, Mol Cancer Ther, vol.16, pp.1177-86, 2017.

E. Papa, M. Weller, and T. Weiss, Negative control of the HGF/c-MET pathway by TGF-?: a new look at the regulation of stemness in glioblastoma, Cell Death Dis, vol.8, p.3210, 2017.

M. Hermisson, A. Klumpp, and W. Wick, O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells, J Neurochem, vol.96, pp.766-76, 2006.

C. Happold, P. Roth, and W. Wick, Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells, J Neurochem, vol.122, pp.444-55, 2012.

T. Glaser, B. Wagenknecht, and P. Groscurth, Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells, Oncogene, vol.18, pp.5044-53, 1999.

V. R. Fantin and P. Leder, F16, a mitochondriotoxic compound, triggers apoptosis or necrosis depending on the genetic background of the target carcinoma cell, Cancer Res, vol.64, pp.329-365, 2004.

C. Happold, P. Roth, and M. Silginer, Interferon-? induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells, Mol Cancer Ther, vol.13, pp.948-61, 2014.

M. Silginer, M. Weller, and R. Stupp, Biological activity of tumor-treating fields in preclinical glioma models, Cell Death Dis, vol.8, p.2753, 2017.

H. Schneider, B. Lohmann, and H. Wirsching, Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas, Oncotarget, vol.8, pp.87124-87159, 2017.

A. Zacher, K. Kaulich, and S. Stepanow, Molecular diagnostics of Gliomas using next generation sequencing of a Glioma-tailored gene panel, Brain Pathol Zurich Switz, vol.27, pp.146-59, 2017.

J. D. Lathia, S. C. Mack, and E. E. Mulkearns-hubert, Cancer stem cells in glioblastoma, Genes Dev, vol.29, pp.1203-1220, 2015.

H. Zhong, L. Lu, and K. Leung, An iridium(iii)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent, Chem Sci, vol.6, pp.5400-5408, 2015.

D. R. Green and F. Llambi, Cell death signaling, Cold Spring Harb Perspect Biol, vol.7, p.6080, 2015.

U. Naumann, J. Wischhusen, and S. Weit, Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation, Cell Death Differ, vol.11, pp.1326-1367, 2004.

Y. Su, C. R. Wang, and H. , Novel targeting of transcription and metabolism in Glioblastoma, Clin Cancer Res, vol.24, issue.5, pp.1124-1137, 2018.

J. Wu, C. Bryla, and A. Mccoy, ACTR-69. Phase I trial of TG02 plus dose-dense or metronomic temozolomide for adults with recurrent anaplastic astrocytoma and glioblastoma, Neuro-Oncol, vol.19, p.15, 2017.